Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.33% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
LCTX · Sep 30, 2025
Lineage Cell Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-25-269599General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-98.23% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-2.59% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-102.85% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
88.86% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
32.57% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History16 statesHistory building
Sep 30, 20220/5 normalizedLevel 3Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/6 normalizedLevel 3Sep 30, 20244/6 normalizedLevel 3Dec 31, 20245/6 normalizedLevel 3Mar 31, 20255/6 normalizedLevel 3Jun 30, 20255/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 0.51%
- Current
- 0.33%
- Delta
- -0.18%
- Previous
- -200.33%
- Current
- -98.23%
- Delta
- 102.09%
- Previous
- 96.38%
- Current
- -2.59%
- Delta
- -98.97%
- Previous
- -715.37%
- Current
- -102.85%
- Delta
- 612.52%
- Previous
- 112.33%
- Current
- 88.86%
- Delta
- -23.47%
- Previous
- 44.77%
- Current
- 32.57%
- Delta
- -12.20%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · LCTX Fundamental State →Transitioned To · LCTX Fundamental State →Transitioned To · LCTX CAPEX_INTENSITY_DECREASED →Transitioned To · LCTX CASH_GENERATION_INCREASED →Transitioned To · LCTX GROWTH_DECREASED →Transitioned To · LCTX PROFITABILITY_INCREASED →Transitioned To · LCTX R_AND_D_INTENSITY_DECREASED →Transitioned To · LCTX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.